Eli Lilly's diabetes and weight-loss drug, Mounjaro, has received a "positive" response in India, with the company now focusing on meeting the significant demand in the world's most populous country. Lilly launched Mounjaro in India in March, ahead of competitor Novo Nordisk, tapping into a market grappling with increasing rates...
Eli Lilly Launches Anti-Obesity Drug in India
U.S. drugmaker Eli Lilly & Co. has introduced Mounjaro in India, the country's first treatment of its kind for obesity, with monthly costs ranging from $168 to $210. The medication is approved for weight loss in patients both with and without type-2 diabetes. Industry experts anticipate competition to intensify soon...
India’s Generic Drugmakers to Develop Options to Wegovy
Indian generic drugmakers such as Sun Pharma, Cipla, Dr Reddy's and Lupin are beginning to develop their own versions of Novo Nordisk's blockbuster weight-loss drug Wegovy. Some analysts predict the weight-loss drug market could reach $100 billion annually by 2030 as obesity rates rise globally. Novo Nordisk has been unable...
Lilly to Launch Diabetes Drug Mounjaro in India
Eli Lilly is planning to launch its blockbuster type 2 diabetes drug Mounjaro (tirzepatide) in India as early as next year, according to e Reuters. Mounjaro is currently under review by Indian health authorities, with Lilly having submitted data from its global clinical trials that included Indian patients. Tirzepatide, the...